Placebo Cannabis
Smoked placebo cannabis
Loading study record…
The purpose of this study is to determine the pharmacokinetics and pharmacodynamics of inhaled cannabis with varying amounts of delta-9-tetrahydrocannabinol (THC), and cannabidiol (CBD) and to evaluate detection of recently smoked THC in oral fluid.
Locally preserved from ClinicalTrials.govOpen ClinicalTrials.govlast source update 2026-03-20
What this record can show
This locally preserved record separates the registered protocol from source-reported registry results. Neither is a treatment recommendation.
Registry facts
This double-blind placebo controlled, within-subject study study will assess testing devices that can measure biochemical markers in oral fluid and neurocognitive-performance markers of recent cannabis use. Other pharmacodynamic effects of inhaled cannabis with CBD and THC will be determined and the pharmacokinetics of THC, CBD, and respective metabolites will be assessed in whole blood.
Linked local records
Local links use governed condition terms or exact source-reported intervention names. They are navigation candidates, not efficacy claims.
Interventions
Smoked placebo cannabis
Smoked cannabis with CBD
Smoked cannabis with CBD and THC
Smoked cannabis with THC
Eligibility
primary outcomes
Time frame: 6 hours
Peak subjective ratings of drug effects associated with abuse liability and impairment as measured using visual analogue scales (VAS; 1-100mm).
Time frame: 6 hours
Peak blood levels of THC, CBD, 11-OH-THC, and THCCOOH after exposure (Tmax)
Time frame: 6 hour
Trough composite scores on the DRUID App
Time frame: 6 hour
Peak levels of THC in oral fluid after exposure
Publications
No exact PMID-linked public article is currently readable locally.